The validation of Signatera in a new study as a significant prognostic factor for endometrial cancer suggests a potential increase in its adoption in clinical settings. This could lead to higher revenues for Natera from sales of Signatera, as it becomes a more integral part of treatment pathways for endometrial cancer. The positive outcome of the study directly impacts Natera's product portfolio and its position in the market, likely leading to a positive short-term impact on its stock price.